title: Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.
abstract: Yersinia pestis causes plague, a disease with high mortality in humans that can be transmitted by fleabite or aerosol. A US Food and Drug Administration (FDA)-licensed plague vaccine is currently not available. Vaccine developers have focused on two subunits of Y. pestis: LcrV, a protein at the tip of type III secretion needles, and F1, the fraction 1 pilus antigen. F1-V, a hybrid generated via translational fusion of both antigens, is being developed for licensure as a plague vaccine. The rV10 vaccine is a non-toxigenic variant of LcrV lacking residues 271-300. Here we developed Current Good Manufacturing Practice (cGMP) protocols for rV10. Comparison of clinical grade rV10 with F1-V did not reveal significant differences in plague protection in mice, guinea pigs or cynomolgus macaques. We also developed cGMP protocols for rV10-2, a variant of rV10 with an altered affinity tag. Immunization with rV10-2 adsorbed to aluminum hydroxide elicited antibodies against LcrV and conferred pneumonic plague protection in mice, rats, guinea pigs, cynomolgus macaques and African Green monkeys. The data support further development of rV10-2 for FDA Investigational New Drug (IND) authorization review and clinical testing.
authors.affiliation: Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA.
authors.forename: Lauriane E
authors.initials: LE
authors.lastname: Quenee
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Ciletti
authors.forename: Derek
authors.initials: D
authors.lastname: Elli
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Hermanas
authors.forename: Olaf
authors.initials: O
authors.lastname: Schneewind
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D006168:Guinea Pigs; D008251:Macaca; D051379:Mice; D008807:Mice, Inbred BALB C; D010930:Plague / Q000517:prevention & control*; D010931:Plague Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D018419:Primate Diseases / Q000517:prevention & control; D051381:Rats; D012376:Rodent Diseases / Q000517:prevention & control; D016019:Survival Analysis; D014611:Vaccination / Q000379:methods; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D015010:Yersinia pestis / Q000235:genetics / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D010931:Plague Vaccine; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D000536:Aluminum Hydroxide